State Street Health Care Select Sector SPDR ETF (XLV)
| Assets | $39.02B |
| Expense Ratio | 0.08% |
| PE Ratio | 22.29 |
| Shares Out | 264.37M |
| Dividend (ttm) | $2.51 |
| Dividend Yield | 1.74% |
| Ex-Dividend Date | Mar 23, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 38.75% |
| Volume | 7,969,747 |
| Open | 145.24 |
| Previous Close | 146.24 |
| Day's Range | 143.68 - 145.53 |
| 52-Week Low | 127.35 |
| 52-Week High | 160.59 |
| Beta | 0.64 |
| Holdings | 62 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe State Street Health Care Select Sector SPDR ETF (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
58.85% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 13.79% |
| Johnson & Johnson | JNJ | 10.54% |
| AbbVie Inc. | ABBV | 6.74% |
| UnitedHealth Group Incorporated | UNH | 6.09% |
| Merck & Co., Inc. | MRK | 5.39% |
| Amgen Inc. | AMGN | 3.56% |
| Thermo Fisher Scientific Inc. | TMO | 3.33% |
| Intuitive Surgical, Inc. | ISRG | 3.22% |
| Gilead Sciences, Inc. | GILD | 3.14% |
| Abbott Laboratories | ABT | 3.05% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 23, 2026 | $0.59468 | Mar 25, 2026 |
| Dec 22, 2025 | $0.65682 | Dec 24, 2025 |
| Sep 22, 2025 | $0.62487 | Sep 24, 2025 |
| Jun 23, 2025 | $0.63038 | Jun 25, 2025 |
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
| Dec 23, 2024 | $0.62166 | Dec 26, 2024 |
Performance
XLV had a total return of 8.12% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.20%.
News
What Johnson & Johnson Earnings Signal for Healthcare ETFs
With Q1 earnings season well underway, it was Johnson & Johnson (JNJ) giving investors a peek at how the broader healthcare sector might perform. The healthcare giant beat expectations on Tuesday in r...
The Big 3: XLV, BA, SAP
Traders "live for days like these," says @Theotrade's Don Kaufman in referencing Wednesday's volatility. He offers a trio of example options trades he sees as opportunities in the price action.
Health care and industrials are the sectors to put money to work: Crossmark's Victoria Fernandez
Victoria Fernandez, Crossmark Global Investments, joins 'Closing Bell' to discuss the recent price action in oil, the strength in tech stocks and more.
Time for Investors to Get Defensive. Sell Staples and Buy Healthcare.
The market is shaky, software stocks have gone off a cliff, and semiconductor stocks are giving back some of their gain. It's time to tweak your portfolio.
Do More for Your Core: A Tactical Roadmap for Sector Investing
Sector investing — it's a typical strategy for advisors if their clients are looking beyond broad market exposure by targeting a specific sector. The concept is fairly straightforward, but implementin...
As AI Valuations Stretch, Health Care ETFs Step Into The Growth Spotlight
Health care ETFs could emerge as one of the stronger performers in 2026 as investors grow cautious about pricey AI stocks.
Mizuho's Jared Holz on why he is bullish on biotech heading into 2026
Jared Holz, Mizuho, joins 'Power Lunch' to talk how to play healthcare and biotech moving into 2026.
Josh Brown's ‘best stocks in the market': Health Care
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to explain why he's spotlighting Health Care in his "best stocks in the market." The Committee debates their health care s...
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
'Fast Money' traders talk how to play biopharma space
The 'Fast Money' traders talk how to play biopharma space.
Momentum and private assets: The trends driving ETFs to record inflows
ETF inflows are already at record annual flows. Todd Rosenbluth, VettaFi head of research, on what's driving the momentum and the trends that are standing out.
Schwab IMPACT 2025: Record $13T in ETFs & What's Next for ETF Assets
Matt Camuso, Head of ETF Solutions at BNY Investments, says there are $13 trillion of assets in ETFs. That's compared to $5 trillion a year prior.
State Street's Anna Paglia on why the firm is shifting from ETFs to mutual funds
Anna Paglia, State Street Investment Research CBO and chief business officer, joins CNBC's Dom Chu on the type of assets and ETFs State Street is seeing the flows into. She also shares why the firm is...
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin
Right now ahead of Halloween, the real suspense might be in ETF investing strategies. With markets seesawing between hopes for rate cuts and the resilience of earnings, investors are dusting off one o...
AI train is moving to non-tech sectors like financials and health care: BofA's Savita Subramanian
Savita Subramanian, Bank of America Securities head of equity and quantitative strategy, joins 'The Exchange' to discuss the current market catalysts and concerns.
What AMD's OpenAI deal means for Nvidia, healthcare stocks see major gains in 2025
Morning Brief: Market Sunrise anchor Ramzan Karmali examines the biggest market news and stories for October 7, 2025. CFRA research analyst Angelo Zino comes on the program to talk more about AMD's AI...
Confluence of factors are bringing investment into biotech sector, says StemPoint's Michelle Ross
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss Ross' thoughts on the recent news in the biotech space, what the CIO expects to continue and much more.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Every pharma company I cover has U.S. production so tariffs are more bark than bite: BMO's Seigerman
Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'Closing Bell' to discuss President Trump's latest tariff announcement on pharmaceutical companies, where execution needs to happ...
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.
Health care sector is resilient, 'won't stay down forever', says Evan May Wealth's Brooke Evans
Brooke May, Evans May Wealth managing partner, joins 'Closing Bell Overtime' to talk what sectors she is keeping an eye on in this market.
Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.
For investors worried about elevated market valuations, they may be just what the doctor ordered.
Gill: We're at a real inflection point for healthcare
Lisa Gill, JP Morgan healthcare analyst, on “Worldwide Exchange,” says healthcare is at an inflection point, with UnitedHealth poised for long-term gains as big investors bet on a turnaround.
Mizuho's Jared Holz on how to play the underperforming health care sector
Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit by the FDA and his read on the healthcare sector.
Final Trades: Netflix, Wynn Resorts, Buckle and the XLV
The Investment Committee give you their top stocks to watch for the second half.
US FDA announces new program to boost domestic drug manufacturing
The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United Stat...
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Managed care needs to improve to improve health care sector, says Mizuho's Jared Holz
Jared Holz, Mizuho health care sector strategist, joins 'The Exchange' to discuss the pain in the health care sector and if there are any opportunity plays within.
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.
Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both...
I've never seen a setup this negative for health care job growth, says Bancreek's Pachman
CNBC's “Power Lunch” is joined by Eric Pachman, chief analytics officer at Bancreek Capital Advisors, to discuss the U.S. labor market, whether health care jobs are in jeopardy and more.
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Buy America, says John Hancock's Matthew Miskin
Matthew Miskin, John Hancock Investment Management, joins 'The Exchange' to discuss markets, small and mid-caps and the industrial sector.
How pet medicine stocks could cushion your healthcare investments from Trump changes
Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
Final Trade: BABA, JPM, XLV, JBLU
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.